Clinical Genetics · 1990 · 120 citations · 12 references
MedicineMaternal HealthObstetricsEarly DetectionHuman GeneticsPrenatal DiagnosisAntenatal Risk AssessmentFetal Anomaly DetectionPregnancy DiagnosisPrenatal CarePrenatal Genetic DiagnosisPrenatal Risk AssessmentAlpha-fetoprotein BiomarkerBiochemical Screening MarkersCase Detection RateMaternal Age EffectsMaternal Serum Alpha-fetoprotein ScreeningNon-invasive Prenatal TestingPrenatal Diagnosis Of Down SyndromePrenatal Screening Markers
The addition of two new markers in maternal serum, estriol and HCG, to those already known, namely the level of maternal serum alfa-fetoprotein and maternal age, considerably improves the expected results of a screening strategy for Down syndrome. The detection rate is slightly increased from 53.0% to 57.6%, but, more importantly, the false-positive rate decreases from 9.4% to 7.3%. It is our belief that, at least in women aged less than 35 years, a screening strategy based on a combination of maternal age and biochemical markers should be incorporated into antenatal care. For older women, the results of such a maternal serum test may refine counseling for genetic amniocentesis, as a much more explicit risk calculation can be performed than that based on age alone.
12
Statistical Methods in Medical Research.
P. Armitage · Biometrics · 1972 · 4.1K citations
Maternal serum screening for Down's syndrome in early pregnancy.
N J Wald, Howard Cuckle, J. W. Densem et al. · BMJ · 1988 · 974 citations · Full text